Benralizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Prednisone Dependent Eosinophilic Asthma
Conditions
Severe Prednisone Dependent Eosinophilic Asthma
Trial Timeline
Apr 26, 2018 → Nov 30, 2022
NCT ID
NCT03470311About Benralizumab + Placebo
Benralizumab + Placebo is a phase 3 stage product being developed by AstraZeneca for Severe Prednisone Dependent Eosinophilic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT03470311. Target conditions include Severe Prednisone Dependent Eosinophilic Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
20 competing products in Severe Prednisone Dependent Eosinophilic Asthma